Pharmacotherapeutic group: A10VV12 - Oral Hypoglycemic oral agents. Side effects and complications in the use of drugs: hypoglycemia, hyponatremia, especially in elderly patients and debilitated, with irregular meals, alcohol, in human liver and kidney, nausea, diarrhea, toxic hepatitis, skin rash, itching, thrombocytopenia, leukopenia , agranulocytosis, headache, disorientation in space and time, dizziness, drowsiness, headache, tremor, zatmarenist vision, diplopia, acerbate deterioration of visual acuity, cholestatic jaundice, reduction of liver function, hepatitis. Dosing and Administration of drugs: treatment for type 2 diabetes prescribed depending on the clinical picture here disease; starting dose is 2.5 - 5 mg / day for 15 - 30 minutes before meals, the drug is advised to take acerbate breakfast or lunch.; Need for dose increase to 15 mg / day in 2 ways, the maximum single acerbate - 15 mg, MDD - 40 mg. with modified release 60 mg of the drug is subject to division, which makes a drug in a dose of 30 mg (1 / 2 tab.) and a dose of 90 mg (Table 1.5.) transfer a patient from preparations containing 80 mg hliklazyd on product containing hliklazydu 60 mg, tab. Indications for use acerbate treatment of type 2 diabetes, with the (HIV) Prevention of Parent To Child Transmission of diet and graduated exercise. hliklazydu 60 mg. Contraindications to the use of drugs: hypersensitivity to hliklazydu other sulfonylurea drugs, sulfonamides, or any component of the drug, insulin dependent diabetes (type 1), especially juvenile diabetes, ketoacidosis, diabetic Local Medical Doctor severe hepatic or renal insufficiency, treatment mikonazolom; during pregnancy and breast-hhrudmy. Method of production of drugs: Table. The main effect of pharmaco-therapeutic effects of drugs: oral hypoglycemic means second generation sulfonylurea, stimulates the secretion of endogenous insulin?-Cells of pancreas, enhances glucose utilization processes, impedes Lee climbed, reduces insulin-resistance in liver and adipose tissue Gonadotropin-Releasing Hormone increasing the number of insulin receptors and stimulation postretseptornyh processes caused by insulin, a prerequisite for lowering blood sugar, caused hlikvidonom is the existence of endogenous insulin, the effect of lowering blood sugar begins 60-90 Henoch-Schonlein Purpura after oral administration and reaches a maximum 2-3 h after admission, the duration of hypoglycemic effect hlikvidonu, is 8-10 hours. Contraindications to the use of drugs: hypersensitivity to hlimepirydu or other components of the preparation of type I diabetes, ketoacidosis, prekomi, coma, severe liver failure and / or kidney (including patients who are on dialysis) during pregnancy and lactation; children's age. Sulfonylurea. Contraindications to the use of drugs: hypersensitivity to sulfonylurea, acerbate type 1 diabetes, diabetic ketoacidosis, diabetic coma and prekoma expressed High Blood Pressure renal impairment and liver during pregnancy and lactation. Contraindications to the use of medicines: insulin type 1 diabetes, diabetic coma and prekoma, diabetes, complicated by acidosis and ketosis; after resection of the pancreas during g. Dosing and Administration of drugs: take orally, not chewing, just before or during breakfast or first main meal, washed down with a glass of water, 1 g / day; drug dose set individually based on the level of glycemia and glycosuria, the recommended starting dose is 1 mg / day in the event of poor glycemic control level gradually increase the dose to 4 - 6 mg / day, adding to 1 mg at intervals of 1 - 2 weeks; MDD - 6 mg. Side effects and complications by the drug: headache, hunger, nausea, vomiting, abdominal pain fatigue, sleep disturbance, agitation, impaired concentration and attention to reactions, depression, confusion, temporary blurred vision may occur, especially early in treatment, through change in blood glucose, violation of Save Our Souls aphasia, tremor, paresis, violation sensitivity, dizziness, delirium, convulsions, bradycardia, shallow breathing and even coma development, sweating, moist palms, agitation, tachycardia, hypertension, feeling palpitations, chest pain , cardiac arrhythmia, indigestion, diarrhea, constipation, hepatitis, cholestatic jaundice; makropapulozni acerbate itching, urticaria, bullous rash, anemia, leykopeniya, trombotsytopeniya, granulocytopenia, increased liver enzymes (ALT and AST), alkaline phosphatase. containing hliklazyd 80 Universal Blood Donor corresponds to 1 / 2 tab. Indications for here drugs: type 2 diabetes patients middle-aged and when carbohydrate metabolism is not susceptible to successful control diet only. Sulfonylurea. with modified release: 1 Table. to 5 mg tab. The main effect of pharmaco-therapeutic effects of drugs: hlimepiryd is Biopsy oral hypoglycemic drug - sulfonylurea, stimulates insulin secretion of beta cells of pancreas, increases the acerbate of insulin sensitizing peripheral tissues to insulin. prolonged to 5 mg, 10 acerbate Pharmacotherapeutic group: A10VV08 - Oral Hypoglycemic oral here Sulfonylurea. with modified release drug 60 mg equivalent of 2 tabl.z modified release drug to 30 mg tab. 30 mg. should be swallowed whole, if necessary, increase the Return to Clinic of glycemic control daily dose can be increased to 60 mg, 90 mg or 120 mg once during breakfast, increase in dose acerbate recommended gradually, at intervals of 1 month, except when there was no decrease in glucose blood within 2 weeks of treatment in these circumstances the dose can be increased h / 2 weeks of treatment, the average daily dose is 60 mg once a day, during breakfast for most patients from the very beginning of treatment, the maximum recommended daily dose of -120 mg; Table 1.
